Your browser is no longer supported. Please, upgrade your browser.
NERV [NASD]
Minerva Neurosciences, Inc.
Index- P/E- EPS (ttm)-0.54 Insider Own0.80% Shs Outstand41.92M Perf Week21.93%
Market Cap138.94M Forward P/E- EPS next Y-0.75 Insider Trans-1.62% Shs Float41.13M Perf Month27.13%
Income-20.70M PEG- EPS next Q-0.18 Inst Own70.20% Short Float5.23% Perf Quarter2.82%
Sales41.20M P/S3.37 EPS this Y-43.10% Inst Trans0.03% Short Ratio2.54 Perf Half Y-7.61%
Book/sh1.38 P/B2.38 EPS next Y-2600.00% ROA-29.80% Target Price- Perf Year-61.32%
Cash/sh- P/C- EPS next 5Y- ROE-51.20% 52W Range1.81 - 15.22 Perf YTD40.17%
Dividend- P/FCF- EPS past 5Y16.20% ROI- 52W High-78.44% Beta1.44
Dividend %- Quick Ratio6.50 Sales past 5Y- Gross Margin- 52W Low81.22% ATR0.19
Employees13 Current Ratio6.50 Sales Q/Q- Oper. Margin- RSI (14)65.77 Volatility8.38% 5.62%
OptionableYes Debt/Eq0.00 EPS Q/Q45.90% Profit Margin-50.20% Rel Volume0.68 Prev Close3.19
ShortableYes LT Debt/Eq0.00 EarningsNov 02 BMO Payout- Avg Volume848.19K Price3.28
Recom2.00 SMA2024.95% SMA5011.08% SMA200-26.53% Volume577,308 Change2.82%
Jun-08-20Reiterated H.C. Wainwright Buy $20 → $10
May-14-20Initiated BTIG Research Buy $23
Oct-02-19Reiterated Chardan Capital Markets Buy $17
Sep-25-19Initiated Chardan Capital Markets Buy $17
Sep-18-19Initiated William Blair Outperform
May-31-19Initiated H.C. Wainwright Buy
Sep-01-17Initiated Citigroup Buy $11
Mar-06-17Resumed Jefferies Buy $17
May-12-16Resumed Jefferies Buy
Jan-22-21 06:20PM  
05:30PM  
Jan-21-21 06:38PM  
05:09PM  
12:59PM  
12:00PM  
11:00AM  
09:30AM  
08:00AM  
Jan-20-21 10:58PM  
06:35PM  
06:00PM  
03:00PM  
02:57PM  
10:50AM  
10:43AM  
09:17AM  
Jan-19-21 02:48PM  
01:20PM  
12:45PM  
12:00PM  
09:00AM  
08:30AM  
08:00AM  
06:20AM  
Jan-18-21 11:15PM  
06:30PM  
05:00PM  
03:35PM  
01:30PM  
12:00PM  
10:43AM  
09:29AM  
08:00AM  
Jan-17-21 10:12AM  
Jan-16-21 11:02PM  
Jan-15-21 05:05PM  
03:52PM  
03:20PM  
02:15PM  
Jan-14-21 12:30PM  
12:06PM  
08:45AM  
08:00AM  
Jan-13-21 06:25PM  
05:00PM  
04:54PM  
03:25PM  
12:35PM  
12:01PM  
Jan-11-21 06:09PM  
05:47PM  
04:30PM  
04:00PM  
01:35PM  
01:00PM  
12:42PM  
09:05AM  
09:00AM  
08:00AM  
Jan-08-21 05:40PM  
05:08PM  
12:45PM  
11:45AM  
11:00AM  
10:04AM  
Jan-07-21 04:40PM  
04:00PM  
06:20AM  
Jan-06-21 10:30PM  
08:30PM  
07:45PM  
06:30PM  
06:00PM  
01:23PM  
11:55AM  
11:50AM  
11:00AM  
09:55AM  
09:26AM  
Jan-05-21 06:20AM  
Jan-04-21 11:48PM  
12:45PM  
12:05PM  
12:00PM  
Jan-03-21 12:10PM  
Jan-02-21 03:12PM  
09:00AM  
Dec-31-20 05:00PM  
04:28PM  
12:20PM  
11:30AM  
Dec-30-20 03:20PM  
02:40PM  
06:20AM  
Dec-29-20 11:10PM  
06:45PM  
06:00PM  
11:25AM  
11:00AM  
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase III clinical trial, a compound for the treatment of schizophrenia. The company is also developing seltorexant that has completed Phase IIb clinical trial for treating insomnia and major depressive disorders; and MIN-301, which is in pre-clinical trial, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of the roluperidone worldwide, excluding Asia; and co-development and license agreement with Janssen Pharmaceutica, N.V. for the development of seltorexant. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was founded in 2007 and is based in Waltham, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Reilly Joseph H.SVP & Chief Operating OfficerDec 16Sale2.643,2288,52231,747Dec 16 08:37 PM
Race GeoffEVP, CFO & CBODec 16Sale2.646,19016,342211,354Dec 16 08:31 PM
Luthringer RemyCEODec 16Sale2.641,3003,43266,490Dec 16 08:29 PM
Ahlholm Frederick WSVP, Chief Accounting OfficerDec 16Sale2.641,8454,87110,039Dec 16 08:29 PM
VAN HEEK G JANDirectorSep 10Buy2.977,00020,79020,333Sep 11 05:13 PM
Ahlholm Frederick WSVP, Chief Accounting OfficerMay 26Sale15.008,339125,0856,884May 27 04:43 PM